This Week in Obstetrics & Gynecology — Aug 2, 2026

Welcome to This Week in Obstetrics and Gynecology. This week we're covering 10 notable papers spanning perinatal medicine and maternal-fetal risk stratification, maternal mental health and substance use, reproductive endocrinology and fertility outcomes, and a practical surgical question about opioid prescribing. Let's dive in.

We'll start with perinatal neuroprotection and placental risk stratification, where two papers in the American Journal of Obstetrics and Gynecology address very different ends of the risk spectrum. The first is a population-based retrospective cohort from the Australian and New Zealand Neonatal Network registry, looking at antenatal magnesium sulfate given before birth under 30 weeks between 2012 and 2020 [2]. This matters because magnesium for fetal neuroprotection has been driven almost entirely by randomised trial data and meta-analysis, with uneven real-world uptake. Among more than sixteen thousand neonates for in-hospital outcomes, and 6,763 infants followed to two to three years, about two thirds of whom were exposed, magnesium exposure was associated with roughly a seventeen percent lower risk of death or cerebral palsy and about a twelve percent lower risk of death or moderate-to-severe functional impairment after adjustment. Cerebral palsy alone was clearly reduced in singleton pregnancies, roughly a third lower, but when multiples were included the reduction was no longer statistically significant. This is observational data with all the confounding that implies, but it's the kind of routine-care confirmation that should push units still running inconsistent magnesium protocols to tighten implementation. The second paper tackles a stubborn problem, stillbirth in pregestational diabetes, where fetal surveillance based on growth clearly isn't capturing everyone at risk [7]. In a masked prospective cohort from New Zealand of 40 people with type 1 and 58 with type 2 diabetes, serial placental growth factor and soluble FMS-like tyrosine kinase 1 measurements were taken every four weeks from 20 to 36 weeks and analysed only after delivery. Two patterns emerged: an early-onset abnormality with a second-trimester placental growth factor below the fifth centile in about a quarter of participants, and a late-onset pattern with an elevated ratio above 38 near 36 weeks in about one in five. For a composite of preterm birth, preeclampsia, or emergency caesarean for intrapartum fetal compromise, the biomarkers together delivered sensitivity and specificity both around 86 percent. By contrast, standard Delphi fetal growth restriction criteria had a sensitivity of just 7 percent. Strikingly, birthweight centiles in the late-onset abnormality group were actually higher than normal, a reminder that in diabetes the placentally compromised fetus can look reassuringly large. This is a small single-country cohort and not yet a reason to change protocols, but it's a strong argument for prospective evaluation of angiogenic markers as an adjunct in diabetic pregnancy.

Moving to maternal mental health and substance use, two papers describe risks that obstetricians are uniquely positioned to modify. In the American Journal of Obstetrics and Gynecology, a retrospective cohort from a large integrated health system followed 6,552 patients with depression who were taking antidepressants in the year before conception [6]. Overall, 37.7 percent developed postpartum depression. Compared with those who continued their antidepressant through pregnancy, patients who stopped, or who stopped and later restarted, had about a fourteen percent higher risk of moderate-to-severe postpartum depression, and stopping was associated with roughly a third higher risk of severe postpartum depression. The strongest signal was in the half of patients who already had at least mild depressive symptoms at their first pregnancy screen; those who also discontinued medication had nearly a threefold higher risk compared with women who continued treatment and had minimal symptoms. Importantly, there were no significant interactions by race, ethnicity, or age, so the message applies across groups. This is observational, and women who stop medication may differ systematically from those who continue, but it gives you concrete numbers for the counselling conversation, and it argues for using the first-trimester depression screen as a decision point rather than a formality. Alongside that, Obstetrics and Gynecology published a cross-sectional analysis of national death certificate data from 2018 through 2023 identifying 2,573 pregnancy-associated drug overdose deaths [8]. The rate rose from 8.0 to 13.0 per 100,000 live births, a relative increase of about 62 percent. Among nonpregnant reproductive-aged women, overdose mortality also rose over the same period, but by about 33 percent, so the increase in pregnant and postpartum people was nearly double. Fentanyl dominated, psychostimulant-involved deaths rose more than twofold, and fentanyl plus stimulant polysubstance deaths accounted for a quarter of all cases, with the highest rates in the South. Practically, this means universal substance use screening, naloxone provision, and, critically, extending postpartum engagement well beyond the six-week visit, because overdose deaths cluster in that later postpartum window that our care model tends to abandon.

Turning to reproductive medicine, three papers converge on how we counsel patients through repeated treatment cycles. Fertility and Sterility published a retrospective cohort of 5,811 patients undergoing 7,763 single euploid embryo transfers at a university-affiliated centre over a decade [4]. The cumulative probability of at least one live birth was 63 percent after a single euploid transfer, 92 percent after three, and 98 percent after five. The per-transfer live birth rate fell from 63 percent on the first attempt to 54 percent on the second, then plateaued, meaning that a failed transfer does not condemn subsequent ones. Fewer than five percent of patients met criteria for recurrent implantation failure after three euploid transfers, and fewer than two percent still had no live birth after five. The obvious caveat is survivor bias, since these are patients with enough euploid embryos to keep going, but the practical implication is that persistence with sequential transfer, rather than an expensive diagnostic workup after one or two failures, is the evidence-supported default. That sits directly alongside the new Fertility and Sterility committee opinion on recurrent implantation failure, which reviews the diagnostic criteria and lays out an evidence-based evaluation for patients with several unsuccessful transfers [3]. Read together, the message is that the definition of recurrent implantation failure should be applied conservatively, because most of these patients are simply not yet finished. The third fertility paper, in Human Reproduction, addresses congenital anomaly risk using Ontario administrative data covering nearly 275,000 births to women with an infertility diagnosis between 2006 and 2021 [9]. Compared with infertile women who conceived without treatment, the risk of any congenital anomaly was about eleven percent higher after ovulation induction or intrauterine insemination and about 28 percent higher after in vitro fertilisation or intracytoplasmic sperm injection. Multiple birth rates were 2.3, 7.2, and 13.3 percent across those groups, but formal mediation analysis showed multiple birth explained only a minority of the excess risk, with the largest contribution for pulmonary artery stenosis, where it accounted for a third to nearly half of the association. So while single embryo transfer remains the right policy, it will not eliminate this excess risk, and the counselling should reflect that the absolute increase is small but real and not simply a twins problem.

Two remaining papers are more immediately actionable in different settings. In Obstetrics and Gynecology, a noninferiority randomised trial at an academic centre assigned 64 patients undergoing laparoscopic or robotic hysterectomy for benign indications to either acetaminophen and ibuprofen alone, or the same regimen plus twelve five-milligram oxycodone tablets [1]. Mean pain scores on day one were 4.0 in the opioid group and 5.0 in the nonopioid group, and on day seven 2.1 versus 3.1, with confidence intervals meeting the prespecified noninferiority margin of 1.5 points. Satisfaction was high in both arms, and median oxycodone consumption by day seven was one tablet in the opioid group and zero in the nonopioid group. The trial is small and single-centre, and patients in the nonopioid arm could request opioids as a safety valve, but the finding that even patients given opioids barely used them supports defaulting to scheduled acetaminophen and ibuprofen with a rescue pathway rather than routine discharge opioids. Finally, from Nature Medicine, a phase 1/2 randomised trial of a hexavalent maternal group B streptococcus conjugate vaccine, GBS6, in non-pregnant and pregnant participants across South Africa, the United States and the United Kingdom [5]. Among 216 pregnant participants vaccinated between 24 and 36 weeks and their 209 infants, rates of adverse events, serious adverse events, and delivery outcomes were comparable between vaccine and placebo, reactogenicity was mostly mild to moderate, and two neonatal sepsis-related deaths occurred, one in each arm, neither judged vaccine-related. The vaccine produced robust serotype-specific antibody responses in mothers with functional antibody transfer to infants. This is early-phase safety and immunogenicity data, not efficacy, so it does not change practice today, but it's the most tangible progress in decades towards replacing intrapartum antibiotic prophylaxis with maternal immunisation. Rounding out the week, a UK Biobank cohort in Menopause followed nearly 108,000 postmenopausal women for a mean of 14.5 years and found hypertension in 17.2 percent overall, with cumulative incidence rising from 16.6 percent with normal-age menopause to 18.8 percent with early menopause and 22.6 percent with premature menopause; after adjustment, premature menopause carried about a twelve percent higher risk, while surgical menopause showed no independent effect [10].

If you only have time for one paper this week, make it the antidepressant continuation cohort in the American Journal of Obstetrics and Gynecology [6]. It addresses one of the most common and most anxiety-provoking counselling conversations in prenatal care, and it gives you real numbers to replace speculation about whether stopping medication is the safer choice.

Here are the key takeaways from this week in Obstetrics and Gynecology. First, antenatal magnesium sulfate delivers measurable neuroprotective benefit in routine care, not just in trials, so audit and tighten your unit's implementation below 30 weeks. Second, in pregestational diabetes, normal fetal growth is not reassurance; angiogenic biomarkers detected placental dysfunction that growth criteria missed almost entirely. Third, discontinuing antidepressants in pregnancy is associated with higher postpartum depression risk, especially in women already symptomatic at their first prenatal screen. Fourth, pregnancy-associated overdose mortality rose 62 percent from 2018 to 2023, outpacing the rise in nonpregnant women, which makes extended postpartum substance use engagement a mortality intervention, not an optional add-on. Fifth, after a failed euploid transfer, persistence works: cumulative live birth reaches 92 percent by three transfers, so resist the urge to launch an extensive workup too early. And finally, routine opioid prescribing after minimally invasive hysterectomy is not needed; scheduled acetaminophen and ibuprofen with a rescue option performed comparably.

That's your roundup for This Week in Obstetrics and Gynecology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if you have a paper you have been meaning to read, upload the PDF, or paste any link, at audioscholar dot C C. We will turn it into audio like this one, in any of thirty-one languages.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.